BPC-157 20mg — Research Protocol Reference

BPC-157 is administered via subcutaneous injection once daily during the intro phase, then 5 days on / 2 days off throughout the active cycle.

Inject as close to the target tissue or injury site as possible, BPC-157 produces its strongest localised repair response near the injection point.

For gut health applications, any standard subcutaneous site is appropriate.

⚠️ Syringe note: A 3mL micro needle is required for the intro phase of the protocol ⚠️

Research protocols for BPC-157 have used doses of 1–10mcg/kg bodyweight per day. For a 75–80kg adult this translates to approximately 250–800mcg/day. 500mcg/day is the most commonly applied maintenance dose across documented protocols. Inject as close to the target tissue or injury site as possible, BPC-157 produces its strongest localised repair response near the injection point. A 20mg vial at 2mL BAC water yields 40 full doses at 500mcg.

In biohacking forums, 300–500mcg 5 days on / 2 days off for 6–8 week cycles is the most commonly reported protocol, with some users opting for twice-daily dosing at 250mcg during the first 2 weeks of an acute injury phase.

BPC-157 is administered once or twice daily, for acute injury protocols, twice-daily dosing (morning and evening, 10–12 hours apart) delivers more sustained repair signalling at the injury site than a single daily injection.

• Inject near the injury site: Subcutaneous injection as close to the damaged tissue as safely possible, adjacent to a tendon, near a joint, or over the abdominal area for gut protocols, concentrates BPC-157's local repair activity where it is most needed.
• Morning and evening split for acute injury: Twice-daily dosing at 250 mcg per injection (2.5 units) provides continuous repair signalling across the full 24-hour period, which is particularly important during the first 2–4 weeks of an acute injury protocol.
• Once daily for maintenance: For ongoing tissue health, gut healing, or long-term maintenance cycles, once-daily morning dosing at 250–500 mcg is sufficient to sustain the repair and anti-inflammatory signalling BPC-157 is studied for.
• Rest period: The 4-week off period between cycles allows tissue to consolidate repair gains and maintains sensitivity to BPC-157's growth factor receptor activity over repeated runs.

Consistent daily dosing near the target tissue, with twice-daily administration during the acute phase, gives BPC-157's local repair mechanism the best conditions to produce the outcomes documented in research.

• Use a micro-syringe for the intro dose: The 250 mcg intro dose draws to 2.5 units at this concentration, a 0.3 mL micro-syringe with finer markings makes this measurement significantly more accurate than a standard 1 mL insulin syringe.
• Inject subcutaneously near the target tissue: BPC-157's local signalling is strongest when injected into the subcutaneous tissue adjacent to the area being treated, for a shoulder, inject near the joint; for gut healing, inject into the abdominal subcutaneous layer.
• Plan vial volume against your protocol: At 2 mL total volume, the 20mg vial provides enough for 40 days at 500 mcg/day or 80 days at 250 mcg/day, plan your cycle length before reconstituting so the solution is not held beyond the 28–30 day usable window.
• Combine with rest and load management during injury protocols: BPC-157 accelerates repair signalling but does not override the need for appropriate tissue loading, pairing it with a structured rehabilitation approach produces significantly better outcomes than injection alone.
• Rotate injection sites within the target area: Even when injecting near a specific injury site, rotate within a small radius each day to prevent cumulative subcutaneous irritation at any single point.
• Track injury markers from week 2 onward: Improvements in pain, range of motion, and functional capacity typically become noticeable within 2–3 weeks of consistent dosing, logging these from the start of the cycle makes it easier to assess whether the protocol is working.

Taking too much BPC-157 can increase the likelihood of unwanted side effects. Signs that your dose may be too high include:

• Nausea or gastrointestinal discomfort: BPC-157 directly influences gut motility and mucosal signalling, at doses above the studied range, this can manifest as nausea, loose stools, or an unsettled stomach that persists for several hours following injection, particularly in the first week of a new cycle.
• Dizziness or light-headedness after dosing: BPC-157 activates nitric oxide signalling pathways that influence blood vessel dilation, a dose that is too high can produce a transient drop in blood pressure immediately after injection, causing dizziness or a brief faint feeling, especially when standing up quickly.
• Excessive fatigue or sedation: An unexpected and pronounced sense of tiredness following injection, beyond normal post-exercise fatigue, may indicate the dose is above the level the nervous system is currently adapting to, particularly in the early weeks of a cycle.
• Injection site warmth or prolonged redness: Persistent localised warmth or redness that does not resolve within 24 hours at the injection site may reflect that the volume injected is producing more localised vascular activation than the tissue is absorbing comfortably.

If any of these signs occur, reduce the daily dose by 25–30%, or revert to the 250 mcg intro dose, for the remainder of the cycle and allow at least one week to stabilise before reassessing.

A dose may be too low if expected effects are absent after several weeks of consistent administration. Common indicators include:

• No reduction in injury pain or inflammation after 2–3 weeks: BPC-157's anti-inflammatory and repair effects at an effective dose are typically noticeable within the first two weeks, if pain levels, swelling, and functional limitation at the injury site show no measurable improvement after completing the intro phase, the dose may not be reaching the threshold needed to activate meaningful growth factor receptor signalling.
• No improvement in gut symptoms after 3–4 weeks: For gut healing protocols, BPC-157 at an effective dose typically produces noticeable improvements in bloating, gut pain, and bowel regularity within the first 3–4 weeks, if these markers remain unchanged, the dose may be insufficient or the injection site may not be placing the compound close enough to the affected gastrointestinal tissue.
• No change in range of motion or tissue mobility: In musculoskeletal repair protocols, measurable gains in range of motion and reduction in stiffness are among the earliest indicators of effective BPC-157 dosing, a complete absence of these changes after 4 weeks at maintenance dose suggests underdosing or a potency issue with the reconstituted vial.

If these indicators persist after the full intro week at 250 mcg/day, advance to 500 mcg/day and consider switching to twice-daily administration, and confirm the reconstituted solution has been stored correctly at 2–8°C and used within the 28–30 day window.

⚠️ This is for informational purposes only. For medical advice or diagnosis, consult a professional. ⚠️